Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease

Table 3 Plasma NfL, cognitive and motor data in PD patients over different timepoints

Group	Values	Time			Trend p value
Group	Values	Baseline	Year 1	Year 2	Trend p value
Total PD	NfL	16.16 ± 0.62	–	16.11 ± 1.37	0.2881
	MMSE	26.82 ± 0.23	26.58 ± 0.25	26.9 ± 0.25	0.4523
	MoCA	25.06 ± 0.29	25.05 ± 0.31	25.17 ± 0.30	0.9324
	Motor	21.32 ± 0.76	24.76 ± 0.84	25.96 ± 1.03	< 0.001
TD	NfL	15.79 ± 0.83	–	12.62 ± 0.81	0.1865
	MMSE	26.99 ± 0.30	26.88 ± 0.28	27.13 ± 0.29	0.9128
	MoCA	25.32 ± 0.39	25.35 ± 0.39	25.42 ± 0.38	0.8401
	Motor	20.99 ± 1.19	24.40 ± 1.20	25.46 ± 1.37	< 0.001
PIGD	NfL	15.76 ± 0.96	–	18.39 ± 2.15	0.0474
	MMSE	26.55 ± 0.46	26.06 ± 0.54	26.5 ± 0.46	0.4865
	MoCA	24.47 ± 0.48	24.38 ± 0.63	24.61 ± 0.54	0.8705
	Motor	22.02 ± 1.28	26.17 ± 1.44	26.80 ± 1.77	< 0.001

Abbreviations: PD Parkinson’s Disease; TD Tremor-Dominant; PIGD Postural Instability Gait Disorder; Motor Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores; MoCA Montreal Cognitive Assessment; NfL Neurofilament light chain protein
Values represent the mean ± SD

ISSN: 1750-1326